Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 18/20 | 0.93 |
| ▸ | HTR2C | P28335 | 1/20 | 0.79 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6926340 | 0.92 | MCHR1 (0.92) | MCHR1HTR2CSLC2A1 | |
| SCHEMBL6925443 | 0.92 | MCHR1 (0.81) | MCHR1HTR2CSLC2A1 | |
| SCHEMBL6894756 | 0.90 | MCHR1 (0.76) | MCHR1HTR2CSLC2A1 | |
| SCHEMBL6925349 | 0.90 | MCHR1 (0.81) | MCHR1HTR2CSLC2A1 | |
| SCHEMBL6930454 | 0.89 | MCHR1 (0.81) | MCHR1HTR2CSLC2A1POLB | |
| SCHEMBL6570538 | 0.89 | MCHR1 (0.74) | MCHR1HTR2CSLC2A1CYP1A2POLB | |
| SCHEMBL6892159 | 0.89 | MCHR1 (0.93) | MCHR1HTR2CSLC2A1 | |
| SCHEMBL6926509 | 0.88 | MCHR1 (1.00) | MCHR1HTR2CSLC2A1 | |
| SCHEMBL6898082 | 0.88 | MCHR1 (0.78) | MCHR1HTR2CSLC2A1 | |
| Trifluoroacetic Acid SCHEMBL6569170 | 0.88 | MCHR1 (0.72) | MCHR1HTR2CSLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001766-B1 | COMPOUNDS FOR THE TREATMENT OF CCR5-MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-04-09 | — | — | EP | claimed |
| US-6515027-B1 | Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 | SMITHKLINE BEECHAM CORP. | 2003-02-04 | — | — | US | claimed |
| JP-2002511879-A | — | — | 2002-04-16 | — | — | JP | claimed |
| EP-1001766-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2001-04-04 | — | — | EP | claimed |
| EP-1001766-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | claimed |
| WO-1999001127-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-14 | — | — | WO | claimed |
| EP-4143235-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | IncellDx, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222069-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | INCELLDX, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-1001766-B1 | COMPOUNDS FOR THE TREATMENT OF CCR5-MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6515027-B1 | Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 | SMITHKLINE BEECHAM CORP. | 2003-02-04 | — | — | US | disclosed |